Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

N/A

1(12.5%)

8Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07557537Phase 1Not Yet Recruiting

A Phase 1 Study of KHN707 Tablets in Healthy Participants

Role: lead

NCT07277933Phase 1Not Yet Recruiting

Efficacy and Safety of KHN702 Tablets in Moderate to Severe Post-operative Pain Subjects

Role: lead

NCT07101120Phase 2Not Yet Recruiting

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

Role: lead

NCT07096791Phase 2Not Yet Recruiting

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression

Role: lead

NCT07044960Phase 1Not Yet Recruiting

A Phase 1 Study of KHN702 Tablets in Healthy Subjects

Role: lead

NCT06589817Phase 3Not Yet Recruiting

A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

Role: lead

NCT06393803Phase 1Recruiting

Phase 1 Study of KH607 Tablets

Role: lead

NCT03232710Not ApplicableUnknown

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Role: lead

All 8 trials loaded